key: cord-0794471-j4fyi3qh authors: Chow, Ronald; Herrstedt, Jørn; Aapro, Matti; Chiu, Leonard; Lam, Henry; Prsic, Elizabeth; Lock, Michael; DeAngelis, Carlo; Navari, Rudolph M. title: Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature date: 2021-01-13 journal: Support Care Cancer DOI: 10.1007/s00520-020-05935-7 sha: bc62a0589c444aea3238145533347c2abdb381d2 doc_id: 794471 cord_uid: j4fyi3qh INTRODUCTION: The aim of this study is to rigorously review the efficacy and safety of olanzapine in defined hematology oncology settings including (1) the setting of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) settings (2) at 5 mg and 10 mg doses, and (3) for response rates for use in the acute, delayed, and overall settings post-MEC and HEC. METHODS: Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched through April 23, 2020. The primary efficacy endpoints were the rate of complete response, in the acute (0–24 h post-chemotherapy), delayed (24–120 h post-chemotherapy), and overall (0–120 h post-chemotherapy) phases. The secondary efficacy endpoints were the rates of no nausea and no emesis, for each phase. Safety endpoints were the rate of no serious adverse events (i.e., no grade 3 or 4 toxicities), as assessed by Common Terminology Criteria for Adverse Events (CTCAE) criteria. The Mantel-Haenszel, random-effects analysis model was used to compute risk ratios and accompanying 95% confidence intervals for each endpoint. For endpoints that statistically favored one arm, absolute risk differences were computed to assess whether there is a 10% or greater difference, used as the threshold for clinical significance by MASCC/ESMO. Fragility indices were also calculated for each statistically significant endpoint, to quantitatively assess the robustness of the summary estimate. A cumulative meta-analysis was conducted for each efficacy meta-analysis with more than 5 studies, also using the Mantel-Haenszel random-effects analysis model. RESULTS: Three studies reported on olanzapine for the rescue of breakthrough chemotherapy-induced nausea and vomiting (CINV); 22 studies reported on olanzapine in the prophylactic setting. For studies reporting on HEC patients, olanzapine-containing regimens were statistically and clinically superior in seven of nine efficacy endpoints in the prophylaxis setting. When olanzapine is administered at a 10-mg dose, it is statistically and clinically superior to control patients in eight of nine endpoints among adults. Olanzapine may be effective in the MEC setting and when administered at 5-mg doses, but the paucity of data leads to notable uncertainty. CONCLUSION: Further RCTs are needed in the setting of MEC patients and administration of olanzapine at a lower 5-mg dose, which may be given to reduce the sedative effect of olanzapine at 10 mg. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-020-05935-7. For cancer patients undergoing chemotherapy, chemotherapyinduced nausea and vomiting (CINV) are two prevalent and potentially treatment-limiting side effects [1] . Female patients and younger patients have been reported to be at greater risk [2] [3] [4] . Patients who have experienced vomiting during previous chemotherapy and those with high expectations of severe nausea prior to chemotherapy are at greater risk as well [5] . CINV is classified according to its time of incidence as either acute (0-24 h post-chemotherapy) or delayed (24-120 h post-chemotherapy). CINV that occurs during the course of chemotherapy despite a prophylactic regimen is termed as breakthrough CINV [6, 7] . Only two groups of antiemetics have been developed to target specific biochemical CINV pathways. These include neurokinin (NK) 1 -receptor antagonists (e.g., aprepitant, rolapitant, and netupitant), and serotonergic (5-HT) 3 -receptor antagonists (e.g., ondansetron, palonosetron), whereas dopamine (D) 2 -receptor antagonists (e.g., prochlorperazine, metoclopramide) initially were developed for different indications [8] [9] [10] [11] . Olanzapine was approved by the US Food and Drug Administration as an antipsychotic [12] , but has been used off-label as an antiemetic due to its potential to bind to multiple receptors in the CINV pathway, specifically serotonergic 5-HT 2a , 5-HT 2c , 5-HT 3 , 5-HT 6 , and dopamine D 1 , D 2 , D 3 , and D 4 receptors [13] . Several phase I-II trials first investigated the efficacy and safety of olanzapine [14] [15] [16] [17] [18] [19] . A systematic review and metaanalysis of early phase trials reported that 97.2% and 83.1% of patients achieved complete response (defined as no emesis and no use of rescue antiemetics) in the acute and delayed phase, respectively [20] . A number of phase III randomized controlled trials were subsequently undertaken and published, and multiple systematic reviews and meta-analyses have been conducted [21] [22] [23] [24] [25] [26] [27] . However, no review has separately analyzed antiemetics for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) patients, an important distinction that leads to different clinical guideline recommendations. Notably, the American Society of Clinical Oncology (ASCO) [28] currently recommends olanzapine as part of a four-drug regimen for HEC patients, while the National Comprehensive Cancer Network (NCCN) [29] and the Multinational Association of Supportive Care in Cancer (MASCC)/the European Society for Medical Oncology (ESMO) [30] recommend the four-drug regimen as an option in HEC patients. None of these guidelines, however, recommend olanzapine for MEC patients [28, 30] . Furthermore, each of the published reviews has methodological limitations when appraised using AMSTAR-2, a critical appraisal tool for systematic reviews [31] (Appendix 1 Electronic Supplementary Material). Given the growing interest in olanzapine and the need for a more rigorous review, the aim of this study is to review the efficacy and safety of olanzapine for the prophylaxis and rescue of CINV through a systematic review and meta-analysis. Furthermore, given the large body of existing data, the aim of this review will be to determine the shortfalls of existing literature to provide future direction for olanzapine research in the CINV setting through a cumulative meta-analysis and fragility assessment. The protocol for this review has been included in Appendix 2 Electronic Supplementary Material. The reporting of this review is conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA) checklist [32] . In the interest of conducting a rigorous and comprehensive review, a de novo search strategy was developed to search databases from their beginnings. Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from their beginning to April 24, 2020. Search restrictions were placed, so only English-language clinical trials were identified (Appendix 3 Electronic Supplementary Material). Two independent in-duplicate screenings were conducted. Where disagreements occurred, discussion of discrepancies occurred and consensus achieved, with the input of a senior author if required. Cohen's kappa coefficient was calculated, to report the concordance. Studies were first screened by title and abstract (level 1 screening). Studies were included after level 1 if they reported on olanzapine in a clinical trial for the setting of CINV. These abstracts then underwent full-text screening (level 2 screening) and were eligible for assessment of quantitative synthesis if they compared an olanzapine-containing regimen in one trial arm to a non-olanzapine-containing regimen in the other trial arm(s). Reference lists of included articles after level 2 screening were also assessed, to identify other potentially relevant randomized controlled trials. Studies with less than 5 patients per arm and non-randomized trials were excluded. As with study selection, data extraction was conducted in duplicate and independently. Disagreements were resolved via discussion, to achieve consensus. Study demographics of age range, percentage male, chemotherapy emetogenicity, and the difference between the olanzapine regimen and the comparative regimen were noted. The primary efficacy endpoints were the rate of complete response, in the acute (0-24 h post-chemotherapy), delayed (24-120 h post-chemotherapy), and overall (0-120 h postchemotherapy) phases. The secondary efficacy endpoints were the rates of no nausea and no emesis, for each phase. Safety endpoints were the rate of no serious adverse events (i.e., no grade 3 or 4 toxicities, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) criteria), as reported by authors. Grades 1 and 2 toxicities were not extracted for analysis, due to the paucity of data. When a trial had two olanzapine-containing arms, the data across the two olanzapine arms were summed for analysis and compared to the non-olanzapine-containing arm. The Mantel-Haenszel, random-effects analysis model was used to compute risk ratios (RRs) and accompanying 95% confidence intervals for each endpoint. A p value of less than 0.05 was considered statistically significant in the test for overall effect. Studies were first separately meta-analyzed by regimen intent-whether olanzapine was administered for prophylaxis or for management of breakthrough nausea. It was then analyzed by age, separating studies reporting on adult and children. Adult studies were further meta-analyzed according to chemotherapy emetogenicity, olanzapine dosage, comparative regimens, and study quality; meta-analyses were conducted for the following subgroups of adult studies: For endpoints that statistically favored one arm and had more than 3 included trials, absolute risk differences (RD) were computed to assess whether there is a 10% or greater difference, deemed to be the threshold for clinical significance by MASCC/ESMO [34] . These analyses were performed using Review Manager (RevMan 5.4) by Cochrane IMS. Fragility indices were calculated for each statistically significant endpoint by subgroup, to quantitatively assess the robustness of the summary estimate. Determination of the index involves a series of iterative calculations, until the simulated study results change from statistically significant to statistically insignificant according to the Fisher's exact test. Essentially, the index is the number of control patients that would need to change from a nonevent to an event outcome, to change the statistical conclusion of a trial [35] . These analyses were conducted using Stata 16. A cumulative meta-analysis was conducted for each efficacy meta-analysis with more than 5 studies, also using the Mantel-Haenszel random-effects analysis model. These analyses will allow for the assessment of the impact of each trial on the meta-analysis summary effect size and 95% CI. These analyses were conducted using Comprehensive Meta-Analysis (Version 3) by Biostat. The Cochrane Risk of Bias tool was used to assess the quality of included randomized controlled trials. Four reviewers (RC, LC, ML, CD) independently assessed bias, after which discussion and consensus was used to resolve any discrepancies. Funnel plots were generated to visually assess for publication bias, for each phase of the three efficacy endpoints where there are 5 or more trials; these were generated using Comprehensive Meta-Analysis (Version 3) by Biostat. From the search strategies, 312 records were identified. After removing duplicate records and adding records identified from included trials, 178 records underwent level 1 screening. A total of 34 full-text articles were assessed for eligibility through level 2 screening, at which points 6 were excluded with reason-three were not a randomized controlled trial [36] [37] [38] , one did not investigate olanzapine in the CINV setting [39] , and two did not have an appropriate treatment regimen for inclusion in our review [40, 41] . Of the remaining 28 articles, 25 randomized controlled trials had extractable data and were included in this systematic review and metaanalysis(Appendix 4 Electronic Supplementary Material). Concordance, as measured by Cohen's Kappa, for level 1 screening was 0.86, and 0.84 for level 2 (Appendix 5 Electronic Supplementary Material). Three studies reported on olanzapine for the rescue of breakthrough CINV [42] [43] [44] ; 22 studies reported on olanzapine in the prophylactic setting . Only seven studies (one reporting on rescue of breakthrough CINV, and six reporting on prophylactic CINV) had no corresponding full-text articles [42, 48, 53, 55, 56, 60, 61] . One study reported on olanzapine for children [48] . Among the adult prophylactic studies, 15 reported exclusively on HEC patients [46, 49-52, 55, 56, 58, 60-66] , three exclusively on MEC patients [53, 57, 59] , and three on a patient population that consists of both HEC and MEC patients [45, 47, 54] . Eight studies compared olanzapine to a double-blind placebo-controlled regimen [47, 52, 59, [62] [63] [64] [65] [66] and thirteen used an opened controlled study design-nine studies used a control arm with antiemetics different from the antiemetics in the investigational (olanzapine-containing) arm [46, 49, 51, 53, 55, 56, 58, 60, 61] and four used a control arm with the same antiemetics as in the investigational (olanzapinecontaining) arm except for olanzapine [45, 50, 54, 57] . 17 adult prophylactic studies used 10 mg doses of olanzapine [45, 46, 49-59, 61, 62, 65, 66] , and 3 studies used 5 mg [47, 60, 63] ; 1 used a mix of 5 mg and 10 mg [64] (Table 1) . The risk of bias assessment for each included study is reported in Appendix 6 Electronic Supplementary Material. Over half of all included studies had high risk of bias, due to concerns around lack of blinding. In children, olanzapine was not statistically superior in the acute and overall phases, according to the one study by Long et al. Complete response Acute phase Olanzapine was statistically better than comparative regimens in the acute phase. Among HEC studies, studies using 10 mg olanzapine dosages, studies using a double-blind placebo-controlled design, and open-design studies comparing olanzapine to control regimens of antiemetics not included in the investigational arm, olanzapine was still statistically superior ( Fig. 1.1) . Olanzapine was clinically superior (risk difference greater than 10%) overall, in HEC studies, studies using 10 mg olanzapine doses, and for studies comparing olanzapine in a double-blind placebo-controlled design ( Table 2) . Delayed phase Olanzapine was also statistically and clinically superior in the delayed phase. This statistical and clinical superiority prevails in analyses of HEC studies, studies using 10-mg olanzapine doses, studies administering 5-mg of olanzapine, and studies assessing olanzapine in double-blind placebo control studies ( Fig. 1.2 ; Table 2 ). Overall phase Olanzapine was statistically and clinically superior in the overall phase among all studies, HEC studies, 10mg olanzapine studies, 5-mg olanzapine studies, and doubleblind placebo-controlled studies ( Fig. 1.3 ; Table 2 ). For the acute, delayed, and overall phases, olanzapine was statistically superior to comparative regimens. This observation was similarly noted among HEC studies, studies where 10 mg of olanzapine was administered, and double-blind placebo-controlled trials. Olanzapine was also statistically and clinically superior to opendesign studies using a control arm with different antiemetics than used in the investigational (olanzapinecontaining) arm in the delayed and overall phases ( Fig. 2; Table 2 ). Neither olanzapine nor control arms were statistically superior to the comparator arm in the acute phase. Olanzapine was both statistically and clinically superior in the delayed and overall phases. Olanzapine was statistically and clinically better in the delayed phase among HEC trials and 10-mg olanzapine trials ( Fig. 3 ; Table 2 ). Olanzapine was statistically superior to comparative regimens with respect to complete control, nausea control, and emetic control, according to the one study reporting on each outcome (Fig. 4) . Olanzapine was also clinically superior in all these afore- Olanzapine is as safe as comparative regimens; the risk of serious adverse events is not statistically significant for olanzapine relative to other regimens (Appendix 12, 13 Electronic Supplementary Material). This review is the most rigorous systematic review to date investigating olanzapine in the CINV setting. A protocol was developed prior to the commencement, risk of bias for studies were assessed, and publication bias was assessed; some or all of these three methodological elements were omitted in prior reviews [21] [22] [23] [24] [25] [26] [27] . This review also has the highest statistical power and appraises all the clinically important endpoints. The most recent reviews by Zhou For studies reporting on HEC patients, olanzapine is statistically and clinically superior in seven of nine efficacy endpoints in the prophylaxis setting; only complete emetic control in the acute and overall phases were not statistically different from comparative regimens. Meta-analysis results among studies employing 10-mg doses and among studies comparing olanzapine to placebo-controlled regimens indicated olanzapine as statistically and clinically superior in eight of nine efficacy endpoints for prophylaxis of CINV, with the exception of complete emetic control in the acute phase. These results support the international clinical guidelines [28] [29] [30] in their recommendation of 10-mg olanzapine in addition to standard antiemetic regimens for the prophylaxis of CINV among HEC patients. Furthermore, this review includes important subgroup analyses not previously conducted among prophylactic studies, namely meta-analyzing studies reporting on MEC patients and 5-mg olanzapine dosing. Olanzapine is both statistically and clinically superior in only three of six efficacy endpoints where a 5-mg dosage is employed-complete response in the acute, delayed, and overall phases. However, it is important to note that over 800 patients across 4 studies were metaanalyzed for the efficacy endpoints of complete response; there was much less statistical power relative to meta-analyses looking at HEC patients alone. Furthermore, even for the efficacy endpoints of complete response, these metaanalysis results are much more fragile and less certain than those pertaining to olanzapine administered at 10-mg dose studies. Olanzapine may potentially be superior to comparative regimens when administered in 5-mg doses as indicated by point estimates, but the paucity of data results in low statistical power to find these differences statistically significant. Olanzapine has also recently been reported to be effective at 5mg doses in controlling nausea and vomiting, unrelated to chemotherapy, for patients with advanced cancer [67] . More RCTs are needed in the CINV setting, to evaluate the efficacy of 5-mg olanzapine doses compared to non-olanzapinecontaining regimens. Studies comparing 5-mg doses to 10mg doses are also encouraged; an abstract recently presented by Mukhopadhyay et al. suggests that 5-mg and 10-mg doses may have similar efficacy, although it has no description of drop out patients or chemotherapy regimens in either arm, and no statistical calculations were published [39] . In the MEC setting, olanzapine is reported to be statistically and clinically superior in two of nine efficacy endpoints only-no nausea in the delayed phase, and no emesis in the overall phase. However, as with the results from the metaanalysis of 5-mg doses, there is a paucity of data in this setting. The results are less robust compared to those in the HEC setting, with the recent clinical trials having noticeable impacts on the summary effect size. More RCTs in this setting would allow for a better understanding of olanzapine's true efficacy for MEC patients. Olanzapine is reported to be clinically and statistically superior than other regimens for the rescue of breakthrough CINV. However, this review's results are only supported by one included study for each efficacy endpoint. Results should be interpreted with caution. In both the prophylactic and rescue setting, olanzapine is reported to be equally as safe as other regimens. However, this too should be interpreted with caution, as the key adverse event of sedation is not routinely reported-many studies commonly reported only on serious (i.e., grade 3 or greater toxicity) adverse events, an observation also noted by our group several years ago [26] . It has been well-documented that olanzapine is a strong sedative, and patients commonly experience fatigue, drowsiness, and reduced general activity [20] . In the interest of reducing adverse events, further exploring the reduction of the dosage of olanzapine (i.e. more RCTs reporting on 5-mg olanzapine doses) is encouraged. This review was not without limitations. Ideally, the protocol would have been registered on PROSPERO; given the COVID 19 pandemic, this was not a feasible optionprotocol registration would have required several months, while in hindsight our review was already completed. There were numerous instances where there were high levels of heterogeneity; a random-effects model was applied in all circumstances to try to appropriately account for this. As well, as is the nature of meta-analyses, the results suffer from any intrinsic biases from included RCTs; over half of the studies have notable concerns of bias due to lack of blinding. In conclusion, olanzapine is effective and safe for the prophylaxis and rescue of CINV. It has been well-documented in the HEC setting and when administered at 10-mg doses; it is statistically and clinically superior to comparative regimens, but its sedative properties can make it difficult to use in outpatient settings. It is unclear if olanzapine is effective in the MEC setting and when administered at a lower 5-mg dose, and further RCTs are needed for a more definitive conclusion. The sedative effect associated with 10 mg of olanzapine further corroborates the need for more investigations into using olanzapine at lower doses. The online version contains supplementary material available at https://doi.org/10.1007/s00520-020-05935-7. Authors' contributions All authors contributed substantially to conception and design, or acquisition of data, or analysis and interpretation of data. All authors contributed in drafting the article or revising it critically for important intellectual content. All authors approved the version to be published. Conflict of interest Dr Lock reports consulting fees from Ferring, Abbvie, Sanofi, and AstraZeneca in the past 10 years outside the submitted work. Dr Herrstedt reports personal fees from SOBI and GSK outside the submitted work. Dr Aapro reports personal fees and non-financial support from the Multinational Association for Supportive Care in Cancer, personal fees and non-financial support from European Society of Medical Oncology, personal fees and non-financial support from the European Cancer Organisation, grants and personal fees from Helsinn, personal fees from Tesaro, grants and personal fees from Sandoz, personal fees from Merck USA, personal fees from Vifor, personal fees from Pfizer, personal fees from Taiho, and personal fees from Kyowa Kirin, outside the submitted work. The other authors declare that they have no conflict of interest. Code availability N/A Chemotherapyinduced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Prognostic factors influencing cisplatin-induced emesis: definition and validation of a predictive logistic model Course, patterns and risk-factors for chemotherapy-induced emesis in cisplatinpretreated patients: a study with ondansetron Determinants of postchemotherapy nausea and vomiting in patients with cancer Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapyinduced nausea and vomiting: a systematic review and metaanalysis of randomized controlled trials Oral cannabinoid for the prophylaxis of chemotherapyinduced nausea and vomiting -a systematic review and meta-analysis Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting Efficacy of the combination of neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nauseas and vomiting: a systematic review and meta-analysis of randomized controlled trials Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? -A systematic review and meta-analysis Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and metaanalysis Radio-receptor binding profile of the atypical antipsychotic olanzapine Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer Efficacy and safety of olanzapine combined with aprepitant, palonosetron and dexamethasone for preventing nausea and vomiting by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1303 phase II trial A phase II trial of palonosetron and olanzapine without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group Study A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapyinduced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomized controlled trials Should olanzapine be advocated over conventional antiemetics for the prevention of chemotherapy-induced nausea and vomiting? An updated meta-analysis of randomized control trials Olanzapine for the prevention and treatment of cancerrelated nausea and vomiting in adults Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update NCCN guidelines insights: antiemesis, versions 2 The latest consensus on antiemetics AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index The efficacy, safety and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study Olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a comparative study from Sudan Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial Support Care Cancer Phase III study of comparing dexamethasone on day 1 with day 1-4 with combined neurokinin-1 receptor antagonist, palonosetron and olanzapine in cisplatin-based chemotherapy Low dose olanzapine in chemotherapy induced nausea and vomiting: The ideal 8 pm antiemetic? Treatment of chemotherapy-induced breakthrough nausea and vomiting The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapyinduced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation Clinical research of olanzapine for prevention of chemotherapyinduced nausea and vomiting Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study A pilot study comparing the addition of olanzapine or aprepitant in an antiemetic regimen for highly emetogenic chemotherapy A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy-induced nausea and vomiting Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting Olanzapine for the prevention of chemotherapy-induced nausea and vomiting Olanzapine versus aprepitant in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study The use of olanzapine compared to aprepitant as antiemetic for prevention of chemotherapy induced nausea and vomiting in highly emetogenic chemotherapya randomized trial Olanzapine and omeprazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotherapy for early stage breast cancer Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study Randomized phase II trial to compare the efficacy of haloperidol and olanzapine in the control of chemotherapy-induced nausea and vomiting in Nepal A randomized double-blind, placebocontrolled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) study Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: final results of randomized phase II trial Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy A randomized study of olanzapine-containing versus standard Support Care Cancer antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations